Sanofi, Regeneron PCSK9 trial uses new recruitment tool

Share this article:

Sanofi, Regeneron and the American College of Cardiology announced Thursday that they were taking a team approach to an investigational monoclonal antibody that will target PCSK9, which is associated with LDL levels. The trio will investigate alirocumab, which Sanofi and Regeneron are developing.

The agreement means the ACC's contribution will include identifying Phase III Odyssey Outcomes clinical trial candidates using its Pinnacle registry—the registry's first use for clinical trial recruitment—and assisting with physician- and patient- education programs regarding “the value of clinical trial research.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.